Laniquidar
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 197509-46-9 |
PubChem (CID) | 6450806 |
ChemSpider | 4953357 |
UNII | K3FRN4DDOY |
Chemical and physical data | |
Formula | C37H36N4O3 |
Molar mass | 584.70 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).[1]
References
- ↑ Ross DD (2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best practice & research. Clinical haematology. 17 (4): 641–51. doi:10.1016/j.beha.2004.08.014. PMID 15494300.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.